Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00323687
Status:
COMPLETED
Last Update Posted:
2008-06-09
First Post:
2006-05-05
Brief Title:
SONETT Switch Study to Once Daily HIV Treatment Regimen With Truvada
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
Switch to a Completely ONce Daily Regimen Containing EmtricitabineTenofovir - Fixed Dose Combination Plus Third QD Partner SONETT
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is an unmet medical need for potent ART regimens that make adherence to treatment even easier due to QD dosing offer a good tolerability profile and fit into the daily life of patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None